CRO contribution proves essential in cutting R&D costs
With the cost of drug development expected to reach $1.9bn (€1.5bn) by 2013, the pressure is on to reduce R&D development time and cost without sacrificing clinical success rate.
Archives for September 26, 2006
Drug enters Phase I to test MRSA efficacy
Novexel has announced it is to put forward its novel small molecule antibiotic into Phase I clinical development representing a new class of antibacterials to treat hospital-based infections caused by gram positive pathogens.
Protein centred on for diabetes drug development
Scientists have isolated a single protein that has a key role in diabetes development, which could form the basis for new drug therapies that could effectively treat a disease that has become endemic.
Nastech awarded another grant to develop bird-flu drug
Nastech Pharmaceutical Company has received a new $1.9m (€1.5m) research grant from the US National Institutes of Health (NIH) to further develop its RNAi therapeutics to fight and prevent bird-flu.
Chinese purchase makes Indian gelatine maker world number 2
Sterling Biotech has emerged as the world's second largest gelatine producer after making its first international foray to acquire the gelatine manufacturing facility of Chinese firm China Gelatin.
UK launches nanotechnology reporting scheme to "assess risks"
UK research organisations, biopharmaceutical and food manufacturers, along with those in other industries are been asked to voluntarily provide any information on nanotechnologies they are working on, under a programme launched this week.